Search - tctmd.com

Displaying 201 - 220 of 959

Sort: Relevancy | Date

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Daily News

Similar Outcomes With Enteric-Coated and Uncoated Aspirin: ADAPTABLE

Todd Neale

October 06, 2023

News Daily News

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

Caitlin E. Cox

October 06, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

MESA Data Can Lend Context to Incidental CAC Findings

Yael L. Maxwell

September 29, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Screen for Hypertensive Disorders During Every Prenatal Visit: USPSTF

Michael O'Riordan

September 25, 2023

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

L.A. McKeown

September 18, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Opinion CV Team Dispatch

September 2023 News Roundup

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

Advertisement

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Similar Outcomes With Enteric-Coated and Uncoated Aspirin: ADAPTABLE

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

October 2023 News Roundup

MESA Data Can Lend Context to Incidental CAC Findings

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Screen for Hypertensive Disorders During Every Prenatal Visit: USPSTF

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 2023 News Roundup

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content